^
Association details:
| Biomarker: | HRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Cotellic (cobimetinib) (MEK1 inhibitor) + belvarafenib (RG6185) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
529P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
Published date:
09/13/2021
Excerpt:
Among 19 pts with NRASm melanoma, 5 (26.3%) pts had a confirmed partial response (cPR) and 8 (42.1%) pts reached stable disease. For BRAFm melanoma, 3 out of 9 pts (33.3%) with a canonical V600 mutation and 3 out of 6 pts (50.0%) with non-canonical mutations achieved cPR. Two out of 2 pts (100.0%) with non-canonical BRAFm NSCLC achieved PR (one unconfirmed). Three additional PR occurred: 2 KRAS G13-mutant CRCs and 1 HRAS melanoma....In this study, belva and cobi exhibited encouraging anti-tumor activity in NRASm and BRAFm (canonical and non-canonical) melanoma, and non-canonical BRAFm NSCLC.
Trial ID:
